MSD stops trials of BTK inhibitor for blood cancers
MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Beren's Niemann-Pick drug Lembaz cleared by FDA
The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
White House drops Heidi Overton pick for FDA chief
At the eleventh hour, the White House has rescinded its nomination of Heidi Overton – a staunch Trump ally – to be FDA Commissioner.
GSK gets second cancer drug approval from Nuvalent buy
The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Isomorphic Labs raises $5bn in massive third round
In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Partner Content
The PM Awards aren’t just for agencies. They’re for the peop...
For decades, the PM Awards have been a fixture in the pharma and healthcare communications calendar
PMi Awards 2026: innovation, connection and a changing indus...
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
LEAP HR: Life Sciences Europe
Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences
Rational Based Drug Design Summit Europe
Driving Safer, Faster & More Efficient Discovery Across Europe
Evolution Summit 2027 to Convene Senior Clinical Development...
Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives
